Gray matter structural correlates of fatigue in multiple sclerosis by Nazeri, Aria
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
Gray matter structural correlates of
fatigue in multiple sclerosis
https://hdl.handle.net/2144/19474
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
GRAY MATTER STRUCTURAL CORRELATES OF FATIGUE 
IN MULTIPLE SCLEROSIS  
 
 
 
by 
 
 
 
 
ARIA NAZERI 
 
M.D., Tehran University of Medical Sciences, 2012 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2016  
					 iv	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 
 ARIA NAZERI 
 All rights reserved  
					 iv	
Approved by 
 
 
 
 
 
First Reader _________________________________________________________ 
 Ronald J. Killiany Ph.D. 
 Associate Professor of Anatomy and Neurobiology 
 
Second Reader _________________________________________________________ 
 Charles R.G. Guttmann, M.D. 
 Associate Professor of Radiology 
 
 
					 iv	
ACKNOWLEDGMENT  
 
 
 
I would like to dedicate this thesis to my great friend and mentor Dr. Charles Guttmann; a 
man who gave me the privilege to work under his supervision. I would like to thank him 
for the faith he had in me and for the unsparing guidance I received from him. The 
most important accomplishment of my thesis is not limited to the results as I believe 
making a good friend in Charles is the pinnacle of this beautiful journey.  I would like to 
thank my brother Arash for helping me to understand the essence and the basis of 
quantitative image analysis. I would like to thank my dearest friend Dr. Miklos Palotai 
for giving me the pleasure of working shoulder to shoulder with him on the fatigue 
project. I would like to thank Dr. Ronald Killiany for his advice and instructions over the 
past year. 
Many thanks to my parents for helping me achieving my dreams all my life with their 
support, love, and the encouragement they gave me. At last, I would like to 
thank my lovely wife Niusha for the unconditional love and support she gave during this 
exciting phase of my life.  
 
  
		 v 
GRAY MATTER STRUCTURAL CORRELATES OF FATIGUE 
IN MULTIPLE SCLEROSIS  
ARIA NAZERI 
ABSTRACT 
 
 We aimed to assess whether frontal cortex-striatum-thalamus (FCST) pathway or other 
grey matter (GM) structures are associated with longitudinal patterns of fatigue, namely 
reversible (RF) versus sustained fatigue (SF). 
MS patients enrolled in our prospective cohort were grouped based on their longitudinal 
Modified Fatigue Impact Scale (MFIS) scores: 1. SF: MFIS≥38 at the two most recent 
yearly assessments; 2. RF: MFIS<38 at last assessment, but presence of at least one 
previous MFIS≥38; 3. Never Fatigued (NF): at least five MFIS<38. Accordingly, we 
selected 98 patients (30 SF, 31 RF, 37 NF; age-range:29-66, female/male:76/22, Extended 
Disability Status Scale (EDSS)£6; 13 patients with secondary progressive (SP) MS and 85 
with relapsing remitting (RR) MS in remission). Disability and depression were assessed 
using the EDSS and CES-D, respectively. 3T T1-weighted MRI was used for voxel based 
morphometry (VBM) to survey for GM atrophy associated with fatigue, controlling for 
age, sex and EDSS. Group-wise volumetric comparison was performed on deep GM 
structures identified by VBM, controlling for age, sex, EDSS and CES-D score. 
VBM showed significant inverse relation between the MFIS cognitive subscale score and 
areas within the bilateral fronto-medial and fronto-orbital cortices, anterior striata, thalami, 
temporal poles, insulae and left lateral occipital cortex (peak FWE-p value of 0.021), and 
		 vi 
between the MFIS physical subscale and areas within the bilateral frontal poles, and frontal 
medial cortices (peak FWE-p value of 0.043). Volumetric analysis showed significant 
atrophy in the putamen (RF < NF p<0.0004; SF < NF p<0.0085) and thalamus (RF < NF 
p<0.00048).  
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INTRODUCTION TO MULTIPLE SCLEROSIS 
Epidemiology 
Multiple Sclerosis (MS) is the most common demyelinating disease that solely affects 
the central nervous system (CNS) (Calabresi, 2004; Heesen et al., 2006). MS is one of the 
leading causes of disability in young adults (Ramagopalan & Sadovnick, 2011). MS is 
more prevalent in women, and some studies have suggested that the female to male ratio 
falls between 1.4:1-2.3:1(Alonso & Hernan, 2008). While the incidence of MS is 
increasing between females, the reason behind the increase in female to male ratio in MS 
remains elusive (Dunn & Steinman, 2013). The average age of onset for MS is between 
28-31 years of age (Goodin, 2014). The prevalence of MS is estimated to be about 0.1 
percent in the United Sates (Langer-Gould, Brara, Beaber, & Zhang, 2013). 
Risk Factors 
Several enviornmental risk factors have been suggested for MS. However, a history of 
infectious mononucleosis, anti-Epstein–Barr virus nuclear antigen (EBNA) IgG 
seropositivity, and smoking are well-established risk factors for MS (Belbasis, Bellou, 
Evangelou, Ioannidis, & Tzoulaki, 2015). In addition, the prevalence of MS increases in 
higher latitudes (Alonso & Hernan, 2008). Several studies have suggested that these 
findings can be explained by lower sun exposure and serum vitamin D levels in these 
regions (Orton et al., 2011; Salzer et al., 2012).  
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The risk of developing MS for non-twin siblings is similar to dizygotic twins (3 to 5 
percent). However, this risk increases to 20-39 percent in monozygotic co-twins of patients 
with MS (Sadovnick et al., 1993). This suggests that genetic background plays a 
singnificant role in the pathogenesis of MS. In fact, more than a hundred genetic 
polymorphisms that contribute to the risk of MS have been identified in distinct loci across 
the human genome (Beecham et al., 2013). Among these variants, HLA-DRB1*1501 has 
shown the strongest association with MS (Lincoln et al., 2005). 
Signs and Symptoms  
Since MS lesions are multifocal and the temporal sequence of their appearance is not 
stereotypical, there is significant heterogeneity in the presentation of the disease and the 
symptoms between patients, depending on the regions that has been affected by MS in each 
of them. Although there is no symptom that can be considered specific for MS, there are 
signs and symptoms that can be suggestive of MS. These symptoms include: a) unilateral 
optic neuritis, which is typically characterized by subacute visual loss (Balcer, 2006); b) 
fatigue that affects 53.7% (95%CI 47–61%) of patients with MS (Wood et al., 2013); c) 
Uhthoff phenomenon, which is characterized by an exacerbation of the symptoms due to 
the increase in body temperature (Selhorst & Saul, 1995); d) bilateral internuclear 
ophthalmoplegia, which is a disorder of conjugate lateral gaze; e) Lhermitte sign, which is 
characterized by electric shock feeling associated with bending the neck down (Richards, 
Sampson, Beard, & Tappenden, 2002). Other symptoms include but are not limited to 
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muscular weakness or paralysis, paresthesia, vertigo, pain, bowel dysfunction, urinary 
dysfunction, sexual dysfunction, cognitive dysfunction, and ataxia (Richards et al., 2002). 
Clinical Course 
The clinical course of MS is subcategorized into four clinical subtypes. a) clinically 
isolated syndrome (CIS): is defined as an attack that has a clinical feature of MS,  but does 
not fully meet the McDonald diagnostic criteria; these patients have a high risk for 
developing MS in the future (Lublin et al., 2014); b) relapsing remitting (RR): this course 
is characterized by MS attacks (also referred to as clinical relapses) with subsequent 
recovery or some residual sequelae. Of note, the progression of the disease between clinical 
attacks is minimal; c) secondary progressive (SP): this course follows a typical relapsing-
remitting course, but at some point gradual clinical worsening of the patient occurs 
irrespective of the presence of attacks. Typically it takes 10 to 20 years before RRMS 
converts to SPMS (Eriksson, Andersen, & Runmarker, 2003); d) primary progressive (PP): 
is characterized by progressive worsening from the beginning with sporadic plateaus. 
Notably, PPMS usually presents as a spinal cord syndrome. Older age of onset is frequent, 
as well as a poor prognosis relative to RRMS (Lublin et al., 2014; Rice, Cottrell, Wilkins, 
& Scolding, 2013). 
Diagnosis 
The McDonald criteria for RRMS are as follows (Polman et al., 2011): (i) 
dissemination in space, which requires either the visualization of white matter lesions 
occuring in more than two typical regions for MS [periventricular, juxtacortical, 
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infratentorial, or spinal cord] or the symptoms that can be attributed to two distinct 
regions); (ii) dissemination in time, which either requires more than one attack, 
simultaneous presence of gadolinium-enhancing and non-enhancing lesions on the same 
MRI, or a new lesion on a T2 weighted image.  
Pathology 
The pathological hallmarks of MS are inflammatory demyelination and 
neurodegeneration. Demyelination can occur in both gray matter and white matter (Geurts 
& Barkhof, 2008). T-cells, B-cells, activated microglia, and demyelination are prominent 
features of demyelinating white matter plaques visible in conventional MR imaging of MS 
patients (Figure 1). In addition to focal white matter plaques, white matter not affected by 
focal lesions (sometimes referred to as normal appearing white matter (NAWM)) also 
shows abnormal features such as microglial activation, 
gliosis, mild demyelination, and axonal loss(Moll et 
al., 2011). These pathologies exist in both RRMS and 
SPMS, but neurodegeneration severity and chronic 
demyelination with impaired remyelination tend to 
increase with the progressive phase of the disease 
(Lassmann et al., 2012). Neurodegeneration manifests 
itself as gray matter atrophy in various brain areas (i.e, 
cortical and subcortical structures). The principal 
mechanisms that underly MS-related neurodegeneration are largely unknown. However, 
Figure 1. demyelinated axons 
(arrows), macrophages containing 
myelin debris (arrowheads) and 
dystrophic axons (asterisk) have 
been shown.(Lassmann, van 
Horssen, & Mahad, 2012) 
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various mechanisms have been implicated in MS-induced neurodegeneration. These 
include: axonal injury, energy failure and mitochondrial damage secondary to chronic 
demyelination, iron accumulation and chronic oxidative injury (Mahad, Trapp, & 
Lassmann, 2015).  
Magnetic Resonance Imaging 
Currently, MRI is the imaging modality of choice for MS diagnosis and monitoring of 
disease activity (Sahraian & Eshaghi, 2010). With respect to healthy white matter, lesions 
appear hyperintense on T2-weighted or proton density images and hypointense on T1-
weighted images. MS plaques usually have ovoid shape.  White matter lesions can be best 
identified with a fluid attenuated inversion recovery (FLAIR) sequence that eliminates the 
hyper-intense signal of CSF and therefore improves the sensitivity for detecting 
periventricular lesions (Figure 2).(Klawiter, 2013)   
Figure 2. Hyperintense 
periventricular lesions (also 
known as Dawson fingers) on a 
sagittal fluid attenuated inversion 
recovery (FLAIR) image (Mandell, 
2013). 
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The border of the acute lesions is not as sharp as that of chronic lesions. The appearance 
of enhancing lesions upon I.V. administration of MRI contrast agent is considered as a 
measure of disease activity.(Morgen et al., 2001) Using Magnetization Transfer Imaging 
(MTI) or increasing the dosage of the intravenous Gadolinium will enhance the sensitivity 
of the MRI for detecting the enhancing lesions.(Silver et al., 1997; Wolansky et al., 1994) 
Most lesions appear isointense on T1 weighted images, but if they appear hypointense 
(compared to GM) they are called black holes; the MRI signal tends to normalize due to 
the resolution of the acute inflammation and the associated edema, as well as due to 
remyelination and astrocytosis.(Bitsch et al., 2001) 
It has been argued that the persistence of black holes on T1-weighted images may be 
attributable to axonal injury and loss. The black holes have the potential to be used as a 
measure of MS progression.(Paolillo et al., 2000) The main imaging features that have a 
direct relation with disease severity are the lesion load and the atrophy in either grey or 
white matter.(Klawiter, 2013) It has been suggested that the lesion load in the first five 
years of the disease can predict the disability level in the long run.(Brex et al., 2002) 
Fatigue in MS 
Fatigue affects 53.7% (95%CI 47–61%) of patients with MS (Wood et al., 2013). In 
general, fatigue can be referred to as an excessive sense of tiredness or exhaustion (Comi, 
Leocani, Rossi, & Colombo, 2001). Multiple mechanisms are believed to contribute to 
fatigue in MS: 
	7		
A) Neurogenic: various lines of evidence support that MS-related fatigue results 
from structural and functional abnormalities in the brain (e.g., neurovascular 
coupling impairment, abnormal brain metabolism, and neurodegenerative 
process). Filippi et al. have shown an inverse correlation between the fatigue 
severity score and the blood oxygen level dependent (BOLD) signal of the 
contralateral intraparietal sulcus, ipsilateral rolandic operculum, and thalamus 
during fMRI during finger tapping and 9 hole peg test (Filippi et al., 2002) 
Researchers have also used positron emission tomography (PET) to demonstrate 
that glucose metabolism is decreased in the frontal cortex and the deep gray 
matter structures in MS patients with fatigue. In another study, atrophy in the 
striatum, thalamus, and frontoparietal cortex has been shown to be correlated with 
fatigue in patients with MS (Calabrese et al., 2010). It has also been suggested 
that regional atrophy in the right nucleus accumbens (Nacc), and left superior 
frontal gyrus, right inferior temporal gyrus and the forceps major is more 
pronounced in MS patients with fatigue as opposed to those without fatigue and 
healthy controls (Rocca et al., 2014). Finally, using magnetic resonance 
spectroscopy (MRS) it has been shown that axonal damage is associated with 
fatigue severity (Tartaglia et al., 2004). 
B) Neurotransmitter Imbalance: there is emerging evidence regarding the role of the 
dopaminergic and glutamatergic pathways in fatigue pathophysiology. Firstly, the 
glutamatergic innervation of the striatum from the frontal cortex, secondly, the 
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commonly used antifatigue drug target dopaminergic neurotransmission.(Bamford 
et al., 2004; Dani & Zhou, 2004; Ledinek, Sajko, & Rot, 2013) 
C) Endocrinological factors: dysregulation of the hypothalamic-pituitary-adrenal 
axis has been associated with fatigue symptoms in MS (Gottschalk et al., 2005). 
D) Cytokines: interferon-γ (IFN-γ) and tumor necrosis factor -α(TNF-α) levels are 
higher in MS patients with fatigue (P. Flachenecker et al., 2004; Heesen et al., 
2006). 
Fatigue and Depression 
Fatigue is prevalent in both MS and depression, fatigue and depression have a 
tendency to co-occur in MS. (Wood et al., 2013) The severity of fatigue has been 
decreased when subjects were treated for depression.(Mohr, Boudewyn, Goodkin, 
Bostrom, & Epstein, 2001) It has been suggested that these two are correlated and 
depression and be used as fatigue predictor in patients with MS.(Kroencke, Lynch, & 
Denney, 2000) It has been argued that the severity of fatigue is higher in patients with 
depression and certain symptoms such as sleep problems, and avolition co-occur in both 
depression and fatigue.(Krupp, Serafin, & Christodoulou, 2010; Mills, Young, Pallant, & 
Tennant, 2010) Hence, It seems that the relationship between fatigue and depression is 
complex. 
Objective and Aim 
As discussed earlier, multiple studies have pointed to the potential role of the frontal 
cortex-striatum- thalamus (FCST) pathway(Calabrese et al., 2010; Filippi et al., 2002; 
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Rocca et al., 2014; Tartaglia et al., 2004) in fatigue development associated with MS. 
However, these findings were not always reproducible. We aimed to assess whether 
FCST and other grey matter (GM) structures are associated with longitudinal patterns of 
fatigue, namely reversible (RF) versus sustained fatigue (SF). We hypothesized that 
patients in the SF group would demonstrate more severe atrophy within the FCST, 
unnder the assumption that fatigue is not reversible when determined by irreversible brain 
structural changes. We also hypothesized that fatigue severity in MS is associated with 
cortical and deep gray matter atrophy 
MATERIALS AND METHODS 
Participants 
We selected 98 patients from a larger pool of over 403 patients undergoing a sub-
study of quality of life (QOL) in the Comprehensive Longitudinal Investigation of 
Multiple Sclerosis at Brigham and Women’s Hospital (http://www.climbstudy.org/).  
All patients met the McDonald criteria for relapse-onset MS (2010 revision) (Polman 
et al., 2011) and underwent MRI with the same scanner (see below). The selected patients 
did not meet the exclusion criteria: (i) less than 12 weeks from the last relapse at the time 
of the clinical and quality of life assessment and the MRI scans, and no history of relapse 
between the MRI scan and the MFIS score assessment; (ii) a prior history of significant 
head trauma or any other neurological disease; (iii) a prior history of psychotic disorders; 
(iv) ongoing history of substance abuse; (v) EDSS > 6, (vi) a history of major medical 
illness such as malignancy; (vii) Age > 65; (viii) image acquisition with other scanner 
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than the 3 Tesla Skyra Siemens at BWH-221 Longwood. The age-range of the selected 
patients was 29-66. Thirteen patients were SPMS while the rest of the participants were 
RRMS.  
In the CLIMB study, participants are followed every six months with clinical 
interviews and examination. The patients have completed QOL questionnaires every 
other year, and undergone MRI scan annually. Fatigue and disability were assessed using 
the Modified Fatigue Impact Scale (MFIS)(Guidelines, 1998; Krupp, Alvarez, LaRocca, 
& Scheinberg, 1988) and Expanded Disability Status Scale (EDSS)(Kurtzke, 1983) 
scores, respectively. The severity of depression was evaluated using the Center for 
Epidemiological Studies Depression Scale (CES-D)(Radloff, 1977). We used 38 as the 
cut-off point for MFIS score for being fatigued(P Flachenecker et al., 2002).   
We grouped the patients into 3 distinct categories based on the longitudinal course of 
the MFIS score: (i) sustained fatigue (SF): last two consecutive MFIS score ≥ 38, (ii) 
reversible fatigue (RF): most recent MFIS score was less than 38 while their previous 
MFIS score ≥ 38; (iii) never fatigue (NF): had no prior history of MFIS score  ≥ 38. We 
identified 30 MS patients who met the criterion for the SF group, 31 patients for the RF 
group, and 37 patients for the NF group. These groups were matched by age, sex, disease 
duration, and EDSS. 
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Magnetic Resonance Imaging 
Brain images were acquired at a single site at the Brigham and Women’s Hospital 
(BWH) using a 3 Tesla Siemens Skyra scanner. The following parameters were used for 
the T1-weghted images: repetition time= 2300 ms, echo time= 2.96ms, voxel dimension 
of 1 X 1 X 1 mm3. The following parameters were used for the FLAIR images: repetition 
time= 5000 ms, echo time= 389 ms, voxel dimension of 1 X 1 X 1 mm3. 
 
Lesion Segmentation 
To segment lesions on FLAIR images we used the lesion growth algorithm module 
(LGA) of the lesion segmentation toolbox (LST v2.0.15) implemented in Statistical 
Parametric Mapping [SPM] Toolbox)(Schmidt et al., 2012). As per the LST manual, the 
optimal threshold was determined after running the LGA multiple times with different 
thresholds. We selected 0.1 as the threshold for lesion segmentation. White matter areas 
falsely classified as lesion were manual excluded from the lesion mask using 3DSlicer 
(www.slicer.org). Finally, the lesions were filled on T1-weighted images using the lesion 
filling module of the LST. 
Voxel Based Morphometry 
Voxel-based morphometry (VBM) was performed to detect regional gray matter 
volume differences between groups and gray matter atrophy associated with fatigue 
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severity (J. Ashburner & Friston, 2000). Lesion-filled T1-weighted images were 
preprocessed using the Statistical Parametrical Mapping 12 (SPM 12) VBM toolbox (John 
Ashburner, 2012). We used diffeomorphic anatomical registration through exponentiated 
lie algebra (DARTEL) (J. Ashburner, 2007) to create a study-specific template and register 
structural images to the Montreal Neurological Institute (MNI) space. VBM image analysis 
steps are summarized as follows: (i) tissue segmentation; (ii) creating DARTEL template; 
(iii) normalization to the MNI space. The preprocessed images were merged using fslmerge 
and then smoothed with a Gaussian kernel (σ=4 mm) using fslmaths.  
We used nonparametric permutation analysis implemented in FSL-Randomise for 
(fsl.fmribox.ac.uk/fsl/fslwiki/Randomise) voxel-wise statistical analysis to survey the 
whole brain for potential gray matter atrophy associated with fatigue severity and patient 
groups defined by temporal patterns of fatigue (Nichols & Holmes, 2002). Threshold-free 
cluster enhancement was used to adjust for family-wise error (FWE) correction for multiple 
comparisons (S. M. Smith & Nichols, 2009). Voxels with an FWE-corrected p< 0.05 were 
considered significant. Effects of temporal course and severity of fatigue subscores on local 
gray matter volume were assessed while controlling for age, sex, and EDSS score. 
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Volumetric Analysis 
For volumetric analysis, subcortical gray matter stuctures were segmented using FIRST 
(a model-based segmentation and registration tool implemented in FSL)(Patenaude, 
Smith, Kennedy, & Jenkinson, 2011). Figure 3 shows a sample subcortical segmentation 
result. Subcortical volumes were calculated using  fslstats. We averaged the volume of 
the bilateral putamina, thalami and caudate nuclei in each patient. 
 
Statistical Analysis 
We used general linear models to assess the following effects on the subcortical 
volumes: (i) effects of group membership (SF, RF, and NF) while controlling for age, sex, 
EDSS, and CES-D scores (Bonferroni corrected p-value <0.0166); (ii) effect of fatigue 
severity (MFIS score) while controlling for age, sex, EDSS, and CES-D scores	Unless 
Figure 3. Automated subcortical segmentation using FIRST. 
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noted otherwise, all statistical tests were perfomed using the R statistical package v3.1.3 
(http://cran.r-project.org/). 
RESULTS  
Demographic and Clinical Characteristics of Fatigue Groups 
Demographic and clinical characteristics of the study participants are summarized in 
Table 1. In our sample, there were no significant differences in age, sex, disease duration, 
and EDSS among the fatigue groups (SF, RF, and NF). In contrast, MFIS total score as 
well as all subscores of MFIS (i.e., cognitive, physical, and psychosocial) were 
significantly higher in SF patients than in both the RF and NF groups at their last visit 
(p≤1×10-7; Figure 4). MS patients with RF also showed greater fatigue severity than 
patients in the NF group (MFIS-Total: p=0.007; MFIS-cognitive subscore: p=0.04; 
MFIS-physical subscore: p=0.03; MFIS-psychosocial subscore: p=0.10). 
Table 1. Demographic and clinical characteristics of the study participants. 
Diagnosis All (n=98) SF (n=30) RF (n=31) NF (n=37) 
Age, y, mean (SD) [range] 49.3 (8.4) 
[29-66] 
48.9 (8.9) 
[34-66] 
49.5 (9.8) 
[29-64] 
49.4 (6.7) 
[34-66] 
Sex, Female/Male 76/22 24/6 23/8 29/8 
Disease duration, y, mean (SD) 17.2 (7.5) 17.7 (6.6) 16.9 (8.0) 17.0 (8.1) 
EDSS, mean (SD) 2.0 (1.5) 2.3 (1.5) 2.0 (1.8) 1.8 (1.0) 
MFIS-total, mean (SD) 28.9 (17.5) 50.3 (7.6) 23.2 (9.8) 16.2 (10.6) 
  MFIS-cog, mean (SD) 13.9 (9.0) 24.1 (5.5) 11.0 (5.9) 8.0 (5.9) 
  MFIS-phys, mean (SD) 13.0 (8.4) 22.3 (4.4) 10.7 (6.0) 7.4 (6.0) 
  MFIS-psych, mean (SD) 2.1 (1.8) 3.9 (1.7) 1.5 (1.2) 1.1 (1.2) 
Abbreviations: EDSS: expanded disability status scale; MFIS: Modified Fatigue Impact Scale; 
MFIS-cog: cognitive subscore of MFIS; MFIS-phys: physical subscore of MFIS; MFIS-psych: 
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psychosocial functioning subscore of MFIS; NF: never fatigue; RF: reversible fatigue; SF: 
sustained fatigue. 	
				
 
Association between Fatigue Severity and Clinical Disability 
Across all participants, higher EDSS was associated with higher MFIS total score 
(β=+0.22; p=0.048), MFIS-physical subscore (β=+0.33; p=0.003) and MFIS-
psychosocial subscore (β=+0.22; p=0.047) while controlling for effects of age and sex. In 
contrast, no significant association was observed between MFIS-cognitive subscore and 
EDSS (p=0.6). 
Voxel-based Morphometry 
VBM did not show a significant difference in gray matter regional volume among the 
temporal patterns of fatigue (i.e., SF, RF, and NF groups). Greater MFIS-cognitive 
Figure 4. MFIS Total Score 
differences among the fatigue 
groups (never fatigue, reversible 
fatigue, and sustained fatigue). 
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subscore severity was significantly associated with lower regional gray matter volume in 
various cortical regions encompassing all four lobes and insula along with subcortical 
structures (i.e., putamen, thalamus, and caudate) in both hemispheres (peak FWE-
p=0.021 in right insula; Table 2; Figure 5). 
 
 
Figure 5. VBM results showing brain regions demonstrating significant atrophy with more severe 
cognitive fatigue (MFIS-cognitive subscore; FWE-p<0.05). 
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Table 2. MNI coordinates and volumes of clusters (PFWE<0.05) from voxel-based morphometry 
demonstrating significantly lower gray matter volume with more severe cognitive fatigue among 
participants with multiple sclerosis. 
Cluster 
 
Volume 
(mm3) 
Peak P 
Value 
MNI Coordinate   Gray Matter Regions  
X Y Z 
1 32,943 0.021 39 6 -16.5 Bilateral insulae, caudate nuclei, putamina, 
thalami, planum polare, parahippocampal 
gyri, cingulate gyri, right temporal pole, 
hippocampus left inferior temporal gyrus, and 
precentral gyrus 
 
2 6,715 0.027 -3 45 -28.5 Bilateral fronto-medial cortices and frontal 
poles 
 
3 5,354 0.03 -63 -45 -16.5 Left inferior temporal gyrus, middle temporal 
gyrus, and left angular gyrus 
 
4 4,177 0.041 48 -28.5 52.5 Right posterior central and right inferior 
temporal 
 
5 3,447 0.031 -39 -90 16.5 Left lateral occipital cortex 
6 1,055 0.032 21 64.5 18 Right frontal pole 
7 710 0.038 0 -72 36 Bilateral precuneus cortices 
8 474 0.049 -1.5 -82.5 -4.5 Bilateral intra-calcarine cortices 
9 396 0.046 -4.5 54 19.5 Left paracingulate gyrus 
10 300 0.048 -12 -105 -3 Left occipital pole 
11 254 0.046 61.5 3 33 Right precentral gyrus 
12 106 0.048 36 -60 49.5 Right lateral occipital cortex 
13 17 0.05 -15 34.5 42 Left superior frontal gyrus 
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VBM  showed significant inverse relationship between the physical subscale of MFIS 
with the volume of the bilateral frontal poles, and frontal medial cortices (peak FWE-p 
value of 0.043) 
Subcortical Volumetric Analysis 
  Subcortical volumetric analysis revealed that the average volume of the bilateral 
thalami and putamina are significantly different between the three groups while 
controlling for EDSS, age, gender, and CESD scores (p=0.0078 and p=0.0024 
respectively) but the average bilateral caudate nuclei volumes were not significantly 
different (p=0.084). Further subgroup analysis revealed that there are no differences 
between the SF and RF group with respect to the average thalami and putamina volumes 
while controlling for the EDSS, age, gender, and CESD score (p=0.96 and p=0.81 
respectively), but the average thalami and putamina volumes were significantly larger in 
the NF group vs RF group (p<0.00048, p<0.0005 respectively), and the average putamina 
volumes were significantly larger in NF group vs SF group (p<0.0085) 
Figure 6. VBM results showing 
brain regions demonstrating 
significant atrophy with more 
severe physical fatigue (MFIS-
physical subscore; family-wise 
error corrected-p<0.05). 
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DISCUSSION 
 Fatigue is one of the most prevalent symptoms amongst patients with MS and has 
been considered one of the most troubling symptoms of MS by patients. (Fisk, Pontefract, 
Ritvo, Archibald, & Murray, 1994) Fatigue has serious social implications for the patients; 
it has been reported that it is one of the main reasons of unemployment in MS patients.(M. 
M. Smith & Arnett, 2005) It’s worth to mention that fatigue is one of the main factors that 
determines the quality of life in MS.(Ziemssen, 2009) Fatigue in general is a difficult to 
define symptom as it has different components such as physical and cognitive which are 
different in nature although they are both referred to as fatigue. These components are not 
totally independent and are actually correlated. It has been suggested that fatigue and 
depression usually cluster. One simple explanation for this phenomenon is the existence of 
common risk factors for the emergence of these two, and a shared pathophysiological 
pathway for their development. One study reported a significant relationship between 
fatigue and depression even after correcting for EDSS.(Bakshi, Shaikh, et al., 2000) 
Treatment of depression is associated with decrease in fatigue.(Mohr, Hart, & Goldberg, 
2003) Atrophy in the frontal lobe and lesions in frontal, temporal, and parietal lobes were 
associated with depression in MS.(Bakshi, Czarnecki, et al., 2000) Hence we decided to 
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control for depression score while assessing the association of fatigue and deep gray matter 
atrophy; to meticulously evaluate the relationship of fatigue and gray matter atrophy while 
limiting the effect of other contributing factors. 
To better define fatigue more detailed questionnaires might be needed. On the other hand, 
fatigue development as discussed in the introduction is multifactorial and can not be only 
attributed to neurogenic origins.  
 
We used voxel-wise and volumetric region-of-interest analyses to characterize gray 
matter neural correlates of fatigue severity and groups of patients with different temporal 
course of fatigue. Our study did not show a significant difference between MS patients 
who had sustained fatigue, reversible fatigue, or were free of significant fatigue in their 
follow up. Across all participants included in this study, voxel-wise analysis (using 
VBM) showed that more severe cognitive fatigue was associated with greater atrophy 
mainly in basal nuclei and thalamus along with insular, temporal, and prefrontal cortices. 
In addition, greater physical fatigue was associated with greater medial frontal lobe 
atrophy. Post-hoc region-of-interest volumetric analysis showed significant differences in 
volume when comparing the average size of the bilateral thalami and putamina between 
the NF and RF group. The average volume of the bilateral putamina was also 
significantly larger in the NF vs RF group while there were no significant differences 
between these structures when comparing the SF vs RF group. Contrary to our initial 
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hypothesis, it appears that different temporal patterns of self-reported fatigue are not 
associated with regional atrophy in the grey matter of patients with MS. Grey matter 
atrophy in distinct anatomical regions was however associated with the severity of fatigue 
subscales. 
 We were able to reproduce the previously reported results that linked regional  gray 
matter atrophy in the fronto-temporal lobes, insulae, occipital cortex, caudate nuclei, 
putamina and thalami to the cognitive subscale of fatigue in MS(Andreasen et al., 2010; 
Batista et al., 2012; Sepulcre et al., 2009; Wilting et al., 2016) In contrast to our study, 
none of these studies have corrected their results based on the EDSS scores; hence, we 
were able to compare patients with wider range of EDSS and estimate the effect of gray 
matter atrophy on fatigue development,  specifically the cognitive component, while 
controlling for the EDSS score. Our VBM analysis could not differentiate between the 
three groups(NF, SF, and RF) that were classified based on the temporal course of their 
MFIS scores. This result might be partly explained by the fact that the groups were 
classified based on their total MFIS score over time, rather than by the cognitive subscale 
of fatigue. When pooling all patients, fronto-medial atrophy was correlated with the 
physical component of fatigue.  
We acknowledge that our study had certain limitations: (i) The design of our study 
was cross-sectional, a longitudinal design will help us to better understand the 
relationship of gray matter atrophy with respect to fatigue development; (ii) We did not 
assess the damage to white matter connectivity on fatigue development, either 
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independently or through gray matter atrophy; (iii) Only 57 subjects had their MRI scan 
within a month of MFIS score assesment; The average and standard deviation between 
the MRI scan and the MFIS score assesment were 4.02 months and 5.39 months, 
respectively; (iv) The number of subjects selected for the SF and RF groups were less 
than those in the NF group. 
CONCLUSION 
In addition to the role of the frontal cortex-striatum-thalamus the insula and occipital cortex 
may also be involved in the pathogenesis of fatigue. Cognitive and physical MFIS were associated 
with different gray matter atrophy patterns. Moreover, gray matter atrophy was associated with 
fatigue severity, independently from its temporal course. 
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